Abstract: The present disclosure provides herein monotherapies of a LILRB antagonist (e.g., an anti-LILRB2 antibody or anti-LILRB4 antibody) and combination therapies of the LILRB antagonist (e.g., an anti-LILRB2 antibody or anti-LILRB4 antibody) and a PD-1/PD-L1 axis inhibitor for cancer patients. Wherein the antagonist of LILRB is an anti-LILRB1 antibody, an anti-LILRB2 antibody, an anti-LILRB3 antibody, an anti-LILRB4 antibody, an anti-LILRB5 antibody or an anti-LAIR1 antibody.

Abstract: This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.

Abstract: A screenshot method includes that a terminal responds to a non-stylus operation by entering a screenshot waiting state. When the terminal establishes a connection to the stylus, the terminal detects an operation of the stylus on a touchscreen of the terminal. If an operation of drawing a closed figure with the stylus is detected, the terminal takes a screenshot of interface content in the closed figure drawn with the stylus.

Abstract: The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example, a cancer patient.

Abstract: The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G1 (IgG1) to a subject in need thereof, for example, a cancer patient.

Abstract: The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example, a cancer patient.

Abstract: The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G1 (IgG1) to a subject in need thereof, for example, a cancer patient.

Abstract: A screenshot method includes that a terminal responds to a non-stylus operation by entering a screenshot waiting state. When the terminal establishes a connection to the stylus, the terminal detects an operation of the stylus on a touchscreen of the terminal. If an operation of drawing a closed figure with the stylus is detected, the terminal takes a screenshot of interface content in the closed figure drawn with the stylus.

Abstract: An optical imaging equipment and method. The optical imaging equipment includes an optical microscope, an objective table, a light source module and an objective lens.

Abstract: This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.

Abstract: The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1) to a subject in need thereof, for example, a cancer patient.

Abstract: The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example, a cancer patient, in combination with a PD-1/PD-L1 antagonist, such as an anti-PD-1 antibody.

Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.

Abstract: This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.

Abstract: An optical imaging equipment and method. The optical imaging equipment includes an optical microscope, an objective table, a light source module and an objective lens.

Abstract: An optical imaging equipment and method. The optical imaging equipment includes an optical microscope, an objective table, a light source module and an objective lens.

Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.

Abstract: The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bid to human B7-H4 to a subject in need thereof, for example, a cancer patient.

Abstract: An optical imaging equipment and method. The optical imaging equipment includes an optical microscope, an objective table, a light source module and an objective lens.

Abstract: The present application discloses a dredging system for a pre-paved gravel foundation bed surface in open sea deep water, including a dredging mechanism, which includes a dredging suction head, a power component and a dredging pipeline, wherein the dredging suction head is connected with the dredging pipeline; the dredging pipeline is communicated with the power component; the dredging suction head includes at least one ridge surface suction port and at least one furrow suction port; the openings of all the furrow suction ports are lower than those of all the ridge surface suction ports; a lifting mechanism, which is connected with the dredging suction head and is used for lifting the dredging suction head to the gravel foundation bed surface; a moving mechanism, which is connected with the lifting mechanism and is used for driving the dredging suction head to move within a dredging range of the gravel foundation bed surface.